Follow The Filings

KTTA Pasithea Therapeutics

Pasithea Therapeutics earnings company data as of 4:48 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —
FY2026 Q2 14 Aug EPS — -0.16 —
Rev — — —

Insider trades

Open-market buys and sales by KTTA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All KTTA insider trades
  • $203K bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Coastlands Capital LP 10% owner
    Buy
    $53K 100,000 shares at $0.5300 +2.7% to stake
    Traded Jun 17 Filed Jun 22
    ↗
  2. Lawrence Steinman Director
    Buy
    $100K 133,333 shares at $0.7500 +201% to stake
    Traded Nov 28, 2025 Filed Dec 1, 2025
    ↗
  3. Tiago Marques CEO
    Buy
    $25K 33,333 shares at $0.7500 +83% to stake
    Traded Nov 28, 2025 Filed Dec 1, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 2 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 3.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q QUARTERLY REPORT Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q QUARTERLY REPORT Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
10-K ANNUAL REPORT Filing Doc
SCHEDULE 13G — Filing Doc
8-K 3.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,5.03,5.07,9.01 Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.